TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most frequent cancer in childhood, accounting for 25% of all pediatric malignancy. ALL is a heterogeneous disease that results from the malignant transformation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites [1]. Multimodal treatment has led to a relatively good prognosis for this disease, with cure rates over 80% [2]. Nonetheless, a significant parcel of patients are refractory to treatment and develop chemo-resistance or relapse after a period of time, leading to treatment failure [3].
Source: Leukemia Research - Category: Hematology Authors: Mar ía Sol Brassesco, Julia Alejandra Pezuk, Maria Angelica Cortez, Karina Bezerra Salomão, Carlos Alberto Scrideli, Luiz Gonzaga Tone Tags: Brief communication Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Childhood Cancer | Hematology | Leukemia | Pediatrics